What to Know About Ozempic and Gastroparesis in Florida

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Legal Concerns

If you or a loved one has developed gastroparesis after taking Ozempic, you may be wondering how the dose and length of use factor into the condition. Decades of pharmacovigilance research have established that drug-induced gastrointestinal side effects can vary significantly with exposure levels. This page examines the current medical understanding of the link between Ozempic and gastroparesis, with a focus on dose and duration context.

The Medical Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its mechanism of action includes slowing gastric emptying, which can lead to gastrointestinal adverse effects. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath testing. The pharmacological link between Ozempic and gastroparesis lies in the drug's effect on gastric motility; GLP-1 receptor agonists delay gastric emptying, and prolonged use may exacerbate or unmask gastroparesis in susceptible individuals. Evidence from placebo-controlled trials indicates that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% were associated with Ozempic, including dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data suggest a dose-dependent increase in gastrointestinal symptoms, which may be relevant to the development of gastroparesis.

Mechanistic Pathways and Risk Context

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which inhibit gastric motility and slow gastric emptying. Chronic exposure may lead to sustained impairment of gastric function, potentially resulting in gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation, but delayed onset after months of use has been reported. In clinical trials, gastrointestinal adverse reactions were most common during the initial weeks of treatment, but some patients experienced persistent symptoms leading to discontinuation. Regarding risk anchors, the adequacy of warnings about Ozempic and gastroparesis is a key consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis as a potential adverse effect. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that some patients discontinued due to these reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of explicit language about gastroparesis may raise questions about whether patients and healthcare providers are adequately informed of this risk.

Legal Implications and Florida's Statute of Limitations

For affected patients in Florida, attorney-related considerations include the statute of limitations for filing a product liability claim. In Florida, the statute of limitations for personal injury claims is generally four years from the date of injury, but this can vary based on the specifics of the case, including when the injury was discovered or should have been discovered. Patients who developed gastroparesis after using Ozempic should consult with an attorney to determine the applicable deadline. The timeline between exposure and documented harm is critical; patients must establish that their gastroparesis was caused by Ozempic and that the manufacturer failed to provide adequate warnings. Evidence from clinical trials showing a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo may support causation. In summary, the evidence indicates that Ozempic is associated with a range of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's mechanism of delaying gastric emptying provides a plausible link to gastroparesis. Patients in Florida who have developed gastroparesis after using Ozempic should be aware of the statute of limitations and seek legal advice to evaluate their options. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability for pharmaceutical injuries, is generally four years from the date of injury. However, the clock may start from when the injury was discovered or should have been discovered. It is crucial to consult with an attorney promptly to determine the exact deadline for your case.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This delay in gastric motility can lead to symptoms of gastroparesis, such as nausea, vomiting, and bloating. Clinical trials show a higher incidence of gastrointestinal adverse reactions in patients taking Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.